KOMPAS.com – Since the end of July, China has administered Covid-19 vaccine doses to groups at high risk of infection corona virus SARS-CoV-2 includes medical energy.
This clinical trial will later show whether the vaccine candidate has worked effectively or not.
Reported CNNChinese health officials approved the emergency use of the vaccine developed by Beijing-based drug company Sinopharm on July 22, 2020.
Medical officers, customs and immigration officials, and groups at high risk of contracting Covid-19 are eligible for the vaccine.
Local officials added that they hope to expand the use of the vaccine to workers in other fields in the fall and winter of this year.
“Once we establish an immune system for medical personnel, people working in urban operations, such as in farmers markets, transportation, and in some service industries may receive vaccines immediately,” said Zheng Zhongwei, director of the National Health Commission’s Science and Technology Development Center. China.
Reported Live Science, Tuesday (25/8/2020), this announcement followed news that Russia approved the use of the Covid-19 vaccine for certain groups, including medical workers in mid-August.
China has approved a different vaccine candidate developed, in part, by CanSino Biologics, a company based in Tianjin, for use in military personnel.
The dose of the vaccine has been given to military personnel since last June.
However, none of the Covid-19 vaccine candidates have completed phase 3 clinical trials.
Only phase 3 trials, which often involve tens of thousands of people, can determine whether a vaccine actually prevents Covid-19 infection.
Such trials are an important step in vaccine development, and long-standing US regulations will require a complete phase 3 trial before a Covid-19 vaccine is approved.
The US Food and Drug Administration (FDA) says that the Covid-19 vaccine should reduce the chance of infection by at least 50 percent compared to placebo or non-impact medications used as control variables in a test.